Posting of Annual Report & Notice of AGM

RNS Number : 3602W

ReNeuron Group plc

31 July 2018

 

 

AIM: RENE

31 July 2018

ReNeuron Group plc

("ReNeuron" or the "Company")

Posting of Annual Report and Accounts and Notice of AGM

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2018 and the Notice of the 2018 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at www.reneuron.com.

ReNeuron's AGM will be held at 10.00am on Wednesday 12 September 2018 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

ENDS

Enquiries:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)	[phone]
N+1 Singer Advisory LLP Mark Taylor (Joint Broker)	[phone]

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

ACSWGUBGMUPRGCG